Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mustang Bio, Inc. (MBIO)
USD0.63
-0.03 (-4.59%)
US NASDAQ Healthcare Biotechnology
Address
95 Sawyer Road 2453
Waltham, MA, US
Waltham, MA, US
CEO
Manuel Litchman
Website
mustangbio.com
IPO
2017-08-22
CIK 1680048 ISIN US62818Q3020
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.63
-0.03 (-4.59%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
135.4K
Beta
2.08
Float Shares
6.44M
Free Float %
85.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.69% | +9.12% | -9.57% | -33.65% | -52.48% | -31.69% | -48.85% | -99.78% | -99.97% | -99.99% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
0.63
DCF (Unlevered)
2.93
+363.6%
DCF (Levered)
3.52
+456.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-33.34
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+84.8% ★ Q1'26: -180.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +55.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-19.9% ★ Q1'26: +17.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
—
est: 50.0K (-100.0%)
|
—
|
—
|
11.00M
11.00M – 11.00M
|
55.60M
55.60M – 55.60M
+405.5% YoY
|
| EBITDA |
-30.02M
|
-14.92M
|
-2.39M
|
—
— – —
|
—
— – —
|
| EBIT |
-30.65M
|
-15.75M
|
-2.43M
|
—
— – —
|
—
— – —
|
| Net Income |
-30.66M
est: -4.50B (+99.3%)
|
-15.75M
est: -248.20M (+93.7%)
|
-1.92M
est: -85.89M (+97.8%)
|
-485.91M
-485.91M – -485.91M
-465.7% YoY
|
-252.77M
-252.77M – -252.77M
+48.0% YoY
|
| SGA |
6.76M
|
4.14M
|
3.95M
|
—
— – —
|
—
— – —
|
| EPS |
-17.07
est: -735.00 (+97.7%)
|
-2.57
est: -40.50 (+93.7%)
|
-0.39
est: -17.50 (+97.8%)
|
-99.00
-99.00 – -99.00
-465.7% YoY
|
-51.50
-51.50 – -51.50
+48.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
22
Total invested
369.8K
Insider transactions (90d)
1
Beneficial owners (>5%)
3
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 2.26M | 2.20% | 2.26M | — | 2.26M | — | HC | Delaware | 2022-07-08 | ↗ |
| 2 | Armistice Capital, LLC | 974.9K | 9.99% | — | 974.9K | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 3 | Steven Boyd | 974.9K | 9.99% | — | 974.9K | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
22
-2 vs prev Q
New positions
5
Closed positions
7
Increased
10
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | KESTRA ADVISORY SERVICES, LLC | 111.0K +44.9K (+68.0%) | 108.9K +8.4K (+8.4%) | 1.78% +0.720 pp | 0.00% +0.000 pp | USD1.30 -24.6% | 2 qtrs — |
| 2 | CITADEL ADVISORS LLC | 84.8K +84.8K (+100.0%) | 83.2K +83.2K (+100.0%) | 1.36% +1.358 pp | 0.00% +0.000 pp | USD0.98 +0.0% | 3 qtrs — |
| 3 | BLACKROCK, INC. | 84.7K +— (+0.0%) | 83.1K -45.7K (-35.5%) | 1.36% +0.000 pp | 0.00% +0.000 pp | USD1.51 -35.1% | 4 qtrs — |
| 4 | DRW SECURITIES, LLC | 73.9K +73.9K (+100.0%) | 72.5K +72.5K (+100.0%) | 1.18% +1.185 pp | 0.00% +0.002 pp | USD0.98 +0.0% | 1 qtrs NEW |
| 5 | VANGUARD GROUP INC | 57.9K +— (+0.0%) | 56.8K -31.2K (-35.5%) | 0.93% +0.000 pp | 0.00% +0.000 pp | USD1.52 -35.5% | 2 qtrs — |
| 6 | TWO SIGMA INVESTMENTS, LP | 40.0K +40.0K (+100.0%) | 39.3K +39.3K (+100.0%) | 0.64% +0.641 pp | 0.00% +0.000 pp | USD0.98 +0.0% | 1 qtrs NEW |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 32.3K +5.9K (+22.2%) | 31.7K -8.5K (-21.1%) | 0.52% +0.094 pp | 0.00% +0.000 pp | USD1.28 -23.4% | 4 qtrs — |
| 8 | XTX TOPCO LTD | 24.1K +5.3K (+28.2%) | 23.6K -4.9K (-17.2%) | 0.39% +0.085 pp | 0.00% -0.001 pp | USD1.40 -30.0% | 2 qtrs — |
| 9 | JANE STREET GROUP, LLC | 14.1K +14.1K (+100.0%) | 13.9K +13.9K (+100.0%) | 0.23% +0.226 pp | 0.00% +0.000 pp | USD0.98 +0.0% | 1 qtrs NEW |
| 10 | GSA CAPITAL PARTNERS LLP | 12.8K +12.8K (+100.0%) | 13.0K +13.0K (+100.0%) | 0.21% +0.206 pp | 0.00% +0.001 pp | USD0.98 +0.0% | 1 qtrs NEW |
| 11 | CFO4LIFE GROUP, LLC | 13.0K +2.5K (+23.9%) | 12.7K -3.2K (-20.0%) | 0.21% +0.040 pp | 0.00% -0.001 pp | USD1.42 -31.0% | 2 qtrs — |
| 12 | SBI SECURITIES CO., LTD. | 2.0K +2.0 (+0.1%) | 2.0K -1.1K (-35.4%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD1.38 -29.0% | 5 qtrs — |
| 13 | TOWER RESEARCH CAPITAL LLC (TRC) | 936.00 -396.0 (-29.7%) | 918.00 -1.1K (-54.7%) | 0.02% -0.006 pp | 0.00% +0.000 pp | USD1.10 -10.9% | 4 qtrs — |
| 14 | MORGAN STANLEY | 153.00 -150.0 (-49.5%) | 150.00 -311.0 (-67.5%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD1.30 -24.6% | 4 qtrs — |
| 15 | HARBOUR INVESTMENTS, INC. | 76.00 +— (+0.0%) | 75.00 -41.0 (-35.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.25 -21.6% | 4 qtrs — |
| 16 | BANK OF AMERICA CORP /DE/ | 54.00 +2.0 (+3.8%) | 53.00 -26.0 (-32.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.20 -18.3% | 4 qtrs — |
| 17 | UBS GROUP AG | 44.00 -4.0 (-8.3%) | 43.00 -30.0 (-41.1%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.23 -20.3% | 4 qtrs — |
| 18 | CULLEN/FROST BANKERS, INC. | 13.00 +13.0 (+100.0%) | 13.00 +13.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.92 +6.5% | 1 qtrs NEW |
| 19 | BNP PARIBAS ARBITRAGE, SNC | 6.00 +— (+0.0%) | 6.00 -3.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.17 -16.2% | 4 qtrs — |
| 20 | MAI CAPITAL MANAGEMENT | 3.00 +3.0 (+100.0%) | 3.00 +3.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.67 +46.3% | 1 qtrs NEW |
| 21 | DANSKE BANK A/S | 2.00 +— (+0.0%) | 2.00 -1.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 -2.0% | 4 qtrs — |
| 22 | NBC SECURITIES, INC. | 3.00 +— (+0.0%) | 2.00 -2.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.33 -26.3% | 2 qtrs — |
| 23 | JPMORGAN CHASE & CO | 2.00 +— (+0.0%) | 2.00 -1.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 -2.0% | 4 qtrs — |
| 24 | GROUP ONE TRADING, L.P. | 1.00 +— (+0.0%) | 1.00 -1.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 -2.0% | 4 qtrs — |
| 25 | CITIGROUP INC | — -602.0 (-100.0%) | — -915.0 (-100.0%) | 0.00% -0.010 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 26 | RENAISSANCE TECHNOLOGIES LLC | — -11.8K (-100.0%) | — -17.9K (-100.0%) | 0.00% -0.189 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 16.8K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.98
Neutral
Buys
1
Sells
2
Shares acquired
247.00
Shares disposed
251.00
Cash buys
1.00
Cash sales
2.00
Net activity
-4
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | Litchman Manuel MD | Director / Officer | F-InKind | D | COMMON STOCK | 19 | 0.75 | 14.25 | 1,615 | D | ↗ |
| 2026-01-02 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 278,385 | 0.00 | — | 536,577 | D | ↗ |
| 2025-12-30 | Jin David | Director | P-Purchase | A | COMMON STOCK, PAR VALUE $0.0001 | 247 | 0.96 | 237.61 | 286 | D | ↗ |
| 2025-12-30 | Herskowitz Neil | Director | S-Sale | D | COMMON STOCK, PAR VALUE $0.0001 | 247 | 0.96 | 237.61 | 145 | D | ↗ |
| 2025-12-30 | Chill Adam J. | Director | S-Sale | D | COMMON STOCK, PAR VALUE $0.0001 | 4 | 0.95 | 3.82 | 375 | D | ↗ |
| 2025-09-29 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 59,334 | 0.00 | — | 258,192 | D | ↗ |
| 2025-04-24 | Litchman Manuel MD | Director / Officer | F-InKind | D | COMMON STOCK | 27 | 1.24 | 33.48 | 1,634 | D | ↗ |
| 2025-03-31 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 67,806 | 0.00 | — | 198,858 | D | ↗ |
| 2024-12-31 | Fortress Biotech, Inc. | 10% Owner | — | — | COMMON STOCK, PAR VALUE $0.0001 | 0 | 0.00 | — | 6,552,784 | D | ↗ |
| 2024-10-23 | Jin David | Director | — | — | Common Stock | 0 | 0.00 | — | 1,994 | D | ↗ |
| 2024-06-27 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 575,191 | 0.00 | — | 2,502,991 | — | ↗ |
| 2024-05-31 | Litchman Manuel MD | Director / Officer | F-InKind | D | Common Stock | 1,396 | 0.35 | 488.60 | 83,024 | — | ↗ |
| 2024-01-19 | MURPHY JAMES B | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-02 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 419,092 | 0.00 | — | 1,927,800 | — | ↗ |
| 2023-12-11 | Carney Peter | Officer | — | D | Common Stock | 0 | 0.00 | — | 3,992 | — | ↗ |
| 2023-07-05 | ZELEFSKY MICHAEL J | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 7,246 | 0.00 | — | 18,970 | — | ↗ |
| 2023-07-05 | WEISS MICHAEL S | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 7,246 | 0.00 | — | 49,637 | — | ↗ |
| 2023-07-05 | ROSENWALD LINDSAY A MD | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 7,246 | 0.00 | — | 60,525 | — | ↗ |
| 2023-07-05 | Herskowitz Neil | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 7,246 | 0.00 | — | 19,703 | — | ↗ |
| 2023-07-05 | Chill Adam J. | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 7,246 | 0.00 | — | 19,170 | — | ↗ |
| 2023-04-24 | Litchman Manuel MD | Director / Officer | F-InKind | D | Common Stock | 1,572 | 4.21 | 6.6K | 79,420 | — | ↗ |
| 2023-01-06 | Fortress Biotech, Inc. | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 2,807,008 | 0.00 | — | 22,630,620 | — | ↗ |
| 2022-09-13 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | COMMON STOCK, PAR VALUE $0.0001 | 5,000 | 0.52 | 2.6K | 299,181 | — | ↗ |
| 2022-09-13 | Litchman Manuel MD | Director | P-Purchase | A | COMMON STOCK, PAR VALUE $0.0001 | 5,000 | 0.52 | 2.6K | 1,098,987 | — | ↗ |
| 2022-07-29 | ZELEFSKY MICHAEL J | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 71,664 | 0.00 | — | 175,861 | — | ↗ |
| 2022-07-29 | WEISS MICHAEL S | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 71,664 | 0.00 | — | 135,861 | — | ↗ |
| 2022-07-29 | ROSENWALD LINDSAY A MD | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 71,664 | 0.00 | — | 294,181 | — | ↗ |
| 2022-07-29 | Herskowitz Neil | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 71,664 | 0.00 | — | 186,861 | — | ↗ |
| 2022-07-29 | Chill Adam J. | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 71,664 | 0.00 | — | 178,861 | — | ↗ |
| 2022-06-21 | Litchman Manuel MD | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 61,000 | 0.00 | — | 1,093,987 | — | ↗ |
| 2022-04-24 | Litchman Manuel MD | Director / Officer | F-InKind | D | Common Stock | 1,248 | 12.15 | 15.2K | 80,992 | — | ↗ |
| 2022-04-18 | Lurier Eliot M | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-18 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | COMMON STOCK, PAR VALUE $0.0001 | 4,094 | 0.74 | 3.0K | 222,517 | — | ↗ |
| 2022-03-18 | Litchman Manuel MD | Director | P-Purchase | A | COMMON STOCK, PAR VALUE $0.0001 | 5,000 | 0.74 | 3.7K | 1,032,987 | — | ↗ |
| 2021-12-14 | Achenbach Brian | Officer | S-Sale | D | COMMON STOCK | 4,374 | 1.83 | 8.0K | 144,729 | — | ↗ |
| 2021-12-08 | Achenbach Brian | Officer | A-Award | A | COMMON STOCK | 22,500 | 0.00 | — | 149,103 | — | ↗ |
| 2021-10-27 | Litchman Manuel MD | Director / Officer | P-Purchase | A | COMMON STOCK | 65,000 | 2.24 | 145.6K | 1,027,987 | — | ↗ |
| 2021-10-12 | Achenbach Brian | Officer | S-Sale | D | COMMON STOCK | 4,450 | 2.28 | 10.1K | 126,603 | — | ↗ |
| 2021-08-31 | ROSENWALD LINDSAY A MD | Director | A-Award | A | COMMON STOCK | 1,170 | 2.58 | 3.0K | 218,423 | — | ↗ |
| 2021-08-31 | Litchman Manuel MD | Director / Officer | A-Award | A | COMMON STOCK | 2,746 | 2.58 | 7.1K | 962,987 | — | ↗ |
| 2021-07-30 | Litchman Manuel MD | Director / Officer | P-Purchase | A | COMMON STOCK | 86,206 | 2.91 | 250.9K | 960,241 | — | ↗ |
| 2021-06-28 | ZELEFSKY MICHAEL J | Director | A-Award | A | COMMON STOCK | 13,774 | 0.00 | — | 104,197 | — | ↗ |
| 2021-06-28 | WEISS MICHAEL S | Director | A-Award | A | COMMON STOCK | 13,774 | 0.00 | — | 64,197 | — | ↗ |
| 2021-06-28 | ROSENWALD LINDSAY A MD | Director | A-Award | A | COMMON STOCK | 13,774 | 0.00 | — | 217,253 | — | ↗ |
| 2021-06-28 | Herskowitz Neil | Director | A-Award | A | COMMON STOCK | 13,774 | 0.00 | — | 115,197 | — | ↗ |
| 2021-06-28 | Chill Adam J. | Director | A-Award | A | COMMON STOCK | 13,774 | 0.00 | — | 107,197 | — | ↗ |
| 2021-06-17 | Litchman Manuel MD | Director / Officer | A-Award | A | COMMON STOCK | 61,000 | 0.00 | — | 874,035 | — | ↗ |
| 2021-04-09 | Achenbach Brian | Officer | S-Sale | D | COMMON STOCK | 2,423 | 3.36 | 8.1K | 131,053 | — | ↗ |
| 2021-03-05 | Litchman Manuel MD | Director / Officer | P-Purchase | A | COMMON STOCK | 165,562 | 3.12 | 516.6K | 825,408 | — | ↗ |
| 2021-02-26 | ROSENWALD LINDSAY A MD | Director | A-Award | A | COMMON STOCK | 1,043 | 2.83 | 3.0K | 203,479 | — | ↗ |
| 2021-02-26 | Litchman Manuel MD | Director / Officer | A-Award | A | COMMON STOCK | 5,000 | 2.83 | 14.2K | 659,846 | — | ↗ |
| 2020-12-15 | Litchman Manuel MD | Director / Officer | P-Purchase | A | COMMON STOCK | 100,000 | 2.91 | 291.0K | 654,846 | — | ↗ |
| 2020-12-15 | Achenbach Brian | Officer | A-Award | A | Common Stock | 22,500 | 0.00 | — | 151,774 | — | ↗ |
| 2020-12-14 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | COMMON STOCK | 100,000 | 2.66 | 266.0K | 200,423 | — | ↗ |
| 2020-12-08 | Achenbach Brian | Officer | S-Sale | D | COMMON STOCK | 5,185 | 3.03 | 15.7K | 133,476 | — | ↗ |
| 2020-10-21 | Achenbach Brian | Officer | S-Sale | D | COMMON STOCK | 3,056 | 2.97 | 9.1K | 138,661 | — | ↗ |
| 2020-09-15 | Litchman Manuel MD | Director / Officer | A-Award | A | COMMON STOCK | 61,000 | 0.00 | — | 554,846 | — | ↗ |
| 2020-08-31 | ROSENWALD LINDSAY A MD | Director | A-Award | A | COMMON STOCK | 1,182 | 2.48 | 2.9K | 102,436 | — | ↗ |
| 2020-08-31 | Litchman Manuel MD | Director / Officer | A-Award | A | COMMON STOCK | 5,000 | 2.48 | 12.4K | 493,846 | — | ↗ |
| 2020-07-14 | ZELEFSKY MICHAEL J | Director | A-Award | A | Common Stock | 16,611 | 0.00 | — | 90,423 | — | ↗ |
| 2020-07-14 | WEISS MICHAEL S | Director | A-Award | A | Common Stock | 16,611 | 0.00 | — | 50,423 | — | ↗ |
| 2020-07-14 | ROSENWALD LINDSAY A MD | Director | A-Award | A | COMMON STOCK | 16,611 | 2.48 | 41.2K | 101,254 | — | ↗ |
| 2020-07-14 | Herskowitz Neil | Director | A-Award | A | Common Stock | 16,611 | 0.00 | — | 101,423 | — | ↗ |
| 2020-07-14 | Chill Adam J. | Director | A-Award | A | Common Stock | 16,611 | 0.00 | — | 93,423 | — | ↗ |
| 2020-06-11 | Litchman Manuel MD | Director / Officer | P-Purchase | A | COMMON STOCK | 153,846 | 3.25 | 500.0K | 488,846 | — | ↗ |
| 2020-05-22 | Litchman Manuel MD | Director / Officer | S-Sale | D | COMMON STOCK | 4,025 | 3.04 | 12.2K | 821,383 | — | ↗ |
| 2020-05-22 | Achenbach Brian | Officer | S-Sale | D | COMMON STOCK | 880 | 3.04 | 2.7K | 141,717 | — | ↗ |
| 2020-05-21 | Litchman Manuel MD | Director / Officer | P-Purchase | A | Common Stock | 90,000 | 3.13 | 281.7K | 335,000 | — | ↗ |
| 2020-05-14 | Litchman Manuel MD | Director / Officer | P-Purchase | A | Common Stock | 90,000 | 2.79 | 251.1K | 245,000 | — | ↗ |
| 2020-03-31 | Achenbach Brian | Officer | S-Sale | D | COMMON STOCK | 3,033 | 2.64 | 8.0K | 142,597 | — | ↗ |
| 2020-03-26 | Litchman Manuel MD | Director / Officer | A-Award | A | Common Stock | 122,000 | 0.00 | — | 155,000 | — | ↗ |
| 2020-03-26 | Achenbach Brian | Officer | A-Award | A | Common Stock | 36,250 | 0.00 | — | 129,274 | — | ↗ |
| 2020-03-05 | Litchman Manuel MD | Director / Officer | A-Award | A | Common Stock | 5,000 | 2.48 | 12.4K | 33,000 | — | ↗ |
| 2020-03-05 | Achenbach Brian | Officer | A-Award | A | Common Stock | 524 | 2.48 | 1.3K | 93,024 | — | ↗ |
| 2020-02-28 | ROSENWALD LINDSAY A MD | Director | A-Award | A | COMMON STOCK | 831 | 2.48 | 2.1K | 84,643 | — | ↗ |
| 2019-12-06 | Achenbach Brian | Officer | S-Sale | D | COMMON STOCK | 6,144 | 3.69 | 22.7K | 145,630 | — | ↗ |
| 2019-08-28 | WEISS MICHAEL S | Director | A-Award | A | Common Stock | 13,812 | 0.00 | — | 33,812 | — | ↗ |
| 2019-08-28 | ROSENWALD LINDSAY A MD | Director | A-Award | A | Common Stock | 13,812 | 0.00 | — | 83,812 | — | ↗ |
| 2019-08-28 | Herskowitz Neil | Director | A-Award | A | Common Stock | 13,812 | 0.00 | — | 84,812 | — | ↗ |
| 2019-08-28 | Chill Adam J. | Director | A-Award | A | Common Stock | 13,812 | 0.00 | — | 76,812 | — | ↗ |
| 2019-04-16 | Achenbach Brian | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 92,500 | — | ↗ |
| 2018-12-10 | Litchman Manuel MD | Director / Officer | P-Purchase | A | Common Stock | 8,000 | 3.35 | 26.8K | 28,000 | — | ↗ |
| 2018-12-04 | Litchman Manuel MD | Director / Officer | P-Purchase | A | Common Stock | 7,500 | 3.60 | 27.0K | 20,000 | — | ↗ |
| 2018-11-26 | Litchman Manuel MD | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 3.87 | 19.4K | 12,500 | — | ↗ |
| 2018-11-23 | Herskowitz Neil | Director | P-Purchase | A | COMMON STOCK | 1,000 | 3.96 | 4.0K | 71,000 | — | ↗ |
| 2018-11-21 | Litchman Manuel MD | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 4.21 | 21.0K | 7,500 | — | ↗ |
| 2018-11-20 | Litchman Manuel MD | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 3.89 | 9.7K | 2,500 | — | ↗ |
| 2018-11-20 | Achenbach Brian | Officer | P-Purchase | A | COMMON STOCK | 500 | 3.87 | 1.9K | 57,500 | — | ↗ |
| 2018-11-19 | Achenbach Brian | Officer | P-Purchase | A | COMMON STOCK | 1,000 | 4.25 | 4.3K | 57,000 | — | ↗ |
| 2018-11-16 | Achenbach Brian | Officer | P-Purchase | A | COMMON STOCK | 1,000 | 4.31 | 4.3K | 56,000 | — | ↗ |
| 2018-11-12 | Chill Adam J. | Director | A-Award | A | COMMON STOCK | 1,000 | 4.85 | 4.9K | 63,000 | — | ↗ |
| 2018-11-08 | Chill Adam J. | Director | A-Award | A | COMMON STOCK | 2,000 | 5.34 | 10.7K | 62,000 | — | ↗ |
| 2018-11-02 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | COMMON STOCK | 50,000 | 4.41 | 220.5K | 70,000 | — | ↗ |
| 2018-06-14 | WEISS MICHAEL S | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 20,000 | — | ↗ |
| 2018-06-14 | ROSENWALD LINDSAY A MD | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 20,000 | — | ↗ |
| 2018-06-14 | Herskowitz Neil | Director | A-Award | A | COMMON STOCK | 10,000 | 0.00 | — | 70,000 | — | ↗ |
| 2018-06-14 | Chill Adam J. | Director | A-Award | A | COMMON STOCK | 10,000 | 0.00 | — | 60,000 | — | ↗ |
| 2018-02-02 | Achenbach Brian | Officer | A-Award | A | COMMON STOCK | 55,000 | 0.00 | — | 55,000 | — | ↗ |
| 2017-11-14 | Achenbach Brian | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-06-07 | ZELEFSKY MICHAEL J | Director | — | D | Common Stock | 0 | 0.00 | — | 73,812 | — | ↗ |
| 2017-06-07 | Chill Adam J. | Director | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2017-04-24 | Litchman Manuel MD | Director / Officer | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-03-31 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | Common Stock, $0.0001 par value | 1,600 | 0.00 | — | 10,132,653 | — | ↗ |
| 2017-03-13 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | Common Stock, $0.0001 par value | 767,264 | 0.00 | — | 10,131,053 | — | ↗ |
| 2017-01-31 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | Common Stock, $0.0001 par value | 213,419 | 0.00 | — | 9,363,789 | — | ↗ |
| 2016-12-29 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | Common Stock, $0.0001 par value | 15,806 | 0.00 | — | 9,150,370 | — | ↗ |
| 2016-12-12 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | Common Stock, $0.0001 par value | 11,925 | 0.00 | — | 9,134,564 | — | ↗ |
| 2016-11-30 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | Common Stock, $0.0001 par value | 47,505 | 0.00 | — | 9,122,639 | — | ↗ |
| 2016-10-25 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | Common Stock, $0.0001 par value | 27,264 | 0.00 | — | 9,075,134 | — | ↗ |
| 2016-09-30 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | Common Stock, $0.0001 par value | 47,870 | 0.00 | — | 9,047,870 | — | ↗ |
| 2016-09-26 | WEISS MICHAEL S | Officer | — | I | Common Stock (Restricted) | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2016-09-26 | ROSENWALD LINDSAY A MD | Director | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2016-09-26 | Horin David J | Officer | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-09-26 | Herskowitz Neil | Director | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2016-09-26 | Fortress Biotech, Inc. | 10% Owner | — | D | Common Stock, par value $0.0001 | 0 | 0.00 | — | 9,000,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
7.58M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Manuel Litchman, M.D. President, Chief Executive Officer and Interim Chief Financial Officer | 485.5K | — | — | — | — | 12.5K | 498.0K | 0.00% | ↗ |
| 2 | 2024 | James Murphy Former Interim Chief Financial Officer | — | — | — | — | — | 199.5K | 199.5K | 0.00% | ↗ |
| 3 | 2023 | Manuel Litchman, M.D. President, Chief Executive Officer and Interim Chief Financial Officer | 481.1K | — | 21.1K | — | — | 12.3K | 514.5K | 4.09% | ↗ |
| 4 | 2023 | Manuel Litchman, M.D. President and Chief Executive Officer | 480.8K | — | 21.1K | — | — | — | 501.8K | 4.19% | ↗ |
| 5 | 2023 | Eliot Lurier Interim Chief Financial Officer | — | — | — | — | — | 244.3K | 244.3K | 0.00% | ↗ |
| 6 | 2022 | Manuel Litchman, M.D. President and Chief Executive Officer | 448.3K | 150.0K | 37.8K | — | — | — | 636.1K | 5.95% | ↗ |
| 7 | 2022 | Eliot Lurier Interim Chief Financial Officer | — | — | — | — | — | 282.8K | 282.8K | 0.00% | ↗ |
| 8 | 2022 | Brian Achenbach Senior Vice President of Finance and Corporate Controller | 64.3K | — | — | — | — | — | 64.3K | 0.00% | ↗ |
| 9 | 2021 | Manuel Litchman, M.D. President and Chief Executive Officer | 450.0K | 225.0K | 209.2K | — | — | 852.00 | 885.1K | 23.64% | ↗ |
| 10 | 2021 | Brian Achenbach Senior Vice President of Finance and Corporate Controller | 278.5K | 97.5K | 47.9K | — | — | — | 424.0K | 11.30% | ↗ |
| 11 | 2020 | Manuel Litchman, M.D. President and Chief Executive Officer | 430.0K | 250.0K | 560.3K | — | — | 827.00 | 1.24M | 45.14% | ↗ |
| 12 | 2020 | Brian Achenbach Senior Vice President of Finance and Corporate Controller | 269.0K | 102.4K | 164.7K | — | — | — | 536.1K | 30.72% | ↗ |
| 13 | 2019 | Manuel Litchman, M.D. President and Chief Executive Officer | 415.2K | 100.8K | — | — | — | 820.00 | 516.8K | 0.00% | ↗ |
| 14 | 2019 | Brian Achenbach Senior Vice President of Finance and Corporate Controller | 256.9K | 69.5K | 98.4K | — | — | — | 424.7K | 23.16% | ↗ |
| 15 | 2018 | Manuel Litchman, M.D. President and Chief Executive Officer | 403.1K | 201.6K | — | — | — | 820.00 | 605.5K | 0.00% | ↗ |
| 16 | 2018 | Brian Achenbach Senior Vice President of Finance and Corporate Controller | 231.5K | 69.5K | — | — | — | — | 301.0K | 0.00% | ↗ |
| 17 | 2017 | Manuel Litchman, M.D. President and Chief Executive Officer | 266.8K | 135.5K | — | 5.97M | — | 547.00 | 6.37M | 93.68% | ↗ |
| 18 | 2017 | Brian Achenbach Senior Vice President of Finance and Corporate Controller | 49.3K | 35.0K | 618.8K | — | — | — | 703.0K | 88.01% | ↗ |
| 19 | 2017 | Brian Achenbach Vice President of Finance and Corporate Controller | 49.3K | — | 618.8K | — | — | — | 668.0K | 92.62% | ↗ |
| 20 | 2017 | David J. Horin Interim Chief Financial Officer | — | — | — | — | — | 83.0K | 83.0K | 0.00% | ↗ |
| 21 | 2016 | David J. Horin Interim Chief Financial Officer | — | — | — | — | — | 48.0K | 48.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Manuel Litchman | President, Chief Executive Officer, Interim Chief Financial Officer & Director | 498.3K | — |
| Michael S. Weiss | Executive Chairman | 60.0K | male |
| Greg Furrow | Chief Quality Officer | — | male |
| Peter Carney | Controller & Interim Chief Accounting Officer | — | male |
| Robyn Hunter | Corporate Secretary | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MBIO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
